QuickView: Poised for the next phase
GNI is close to advancing its lead product Etuary (pirfenidone) into pivotal clinical studies in radiation pneumonitis, diabetic nephropathy and other fibrotic diseases. Etuary is commercialised in China for idiopathic pulmonary fibrosis (IPF). The company has global patents for Etuary, and for F351, its improved chemical entity, which is due to move into Phase II for liver fibrosis and potentially chronic kidney disease (CKD), both of which are prevalent in global populations. As GNI moves further forward, the scope to out-license these products in other territories, including the US, should improve.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.